Afimmune is a member of SCDAA’s SCD C.A.R.E.S. Consortium.
“Afimmune is a drug discovery and development company. We are dedicated to improving the quality of life for people with rare blood disorders and inflammatory conditions, including sickle cell disease (SCD). With a strong focus on addressing the unmet needs within SCD, our mission is driven by experienced experts in the field and a deep understanding of the complex challenges faced by patients with rare blood disorders.
With therapies in various stages of clinical and pre-clinical development, Afimmune are diligently working to provide innovative treatment options for patients with SCD. We have highlighted the promising potential of Epeleuton, a therapy that addresses multiple aspects of SCD. Recent results regarding its impact on the adhesion of red blood cells in SCD patients are encouraging, and we are optimistic that, upon approval, Epeleuton could become a safe and effective oral treatment for this debilitating disease.
At Afimmune, we envision a world where people’s lives are transformed beyond the science. We are dedicated to speeding up innovation and collaborating closely with our partners to meet the pressing needs of the sickle cell community. Our objective is not only to create ground-breaking therapy but also to deepen our understanding of the disease, promote equity, and assistance for those affected by SCD and other rare blood disorders. United, we aim to build a brighter future where serious chronic diseases no longer limit lives.”
Learn more about Afimmune’s research.
Featured Clinical Trials
Follow Afimmune on social media
 |
The SCD C.A.R.E.S. Consortium aims to change the perception of clinical trials and increase the participation of sickle cell patients in clinical trials to ultimately provide more therapies to the SCD community. Together, the consortium works together to educate and encourage more trial participation while providing opportunities and better options for the treatment of sickle cell disease.
